Author Archives: admin

Commentary: The Importance of Covid Vaccination in Rural Schools – Daily Yonder

By Diana Outlaw, Associate Professor, Biological Sciences, Mississippi State University To my fellow parents and community members in rural America, After the schools closed in March, 2020, we sat out the remainder of the 2020-2021 school year, opting to keep our exceptional child safe at home. Its not so much that we were worried about her being more vulnerable to Covid but that her poor adaptive skills and general lack of hygiene awareness made us extremely apprehensive about the germ-ridden cesspool of an elementary school

Global Therapeutic Proteins Market Research Report 2022: Focus on Insulin; Fusion Protein; Erythropoietin; Interferon; Human Growth Hormone; Follicle…

DUBLIN--(BUSINESS WIRE)--The "Therapeutic Proteins Global Market Report 2022: By Product, By Application, By Function" report has been added to ResearchAndMarkets.com's offering. The global therapeutic proteins market is expected to grow from $100.06 billion in 2021 to $112.17 billion in 2022 at a compound annual growth rate (CAGR) of 12.1%.

Human Resources offers inclusive benefits to employees – Source

Building a more inclusive community at Colorado State University is a shared goal, and one that Human Resources embraces through offering inclusive benefits to our faculty and staff. Employees may be unaware of medical benefits, leave options and wellness programs that are designed specifically to support all gender identities and people of color.

Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial -…

- VISENs Phase 3 Trial achieved primary endpoint; pediatric growth hormone deficiency (GHD) patients treated with TransCon hGH demonstrated greater annualized height velocity at 52-weeks (p=0.0010) compared to patients treated with daily growth hormone - These results demonstrate the ability of TransCon technology to deliver consistent and reproducible results for patients across a broad range of geographies and populations COPENHAGEN, Denmark, May 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S ( ASND) announced today that results from VISEN Pharmaceuticals Phase 3 trial of once-weekly TransCon hGH in children with GHD in China demonstrated results that were consistent with the Ascendis Pharmas earlier multi-national Phase 3 trial.

Swole Is The Goal: ARod’s Girlfriend Gets A Pump In On Their Italian Vacation – OutKick

Content machines ARod and girlfriend Kathryne Padgett were at it again Monday with the slugger behind the camera as his fitness model girlfriend got swole and then jumped into ocean waters in some undisclosed location. If youve been on a vacation of your own and havent been following along, ARod rented out a ship for yet another summer vacation that includes Padgett, former NFL wide receiver Eric Decker and his wife/singer Jessie James Decker. Others have joined the fray over the last week, but these are the main actors who have been pumping out content for the tabloids.

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Inflection Point (NASDAQ:CRNX) – Seeking Alpha

D-Keine/E+ via Getty Images Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a great speculative biotech play to look into. That's because it is expected that it will release results from two phase 3 studies under the PATHFNDR program in 2023.

Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program – Montreal Gazette

Breadcrumb Trail Links Author of the article: Company advancing AIM Biologicals development program as a potential therapeutic treatment option for neuromyelitisopticaspectrum disorder (NMOSD) Positive results presented at the 13thInternational Congress on Autoimmunity being held in Athens, Greece Preliminary data with mouse 2D2 models of spontaneousautoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms This advertisement has not loaded yet, but your article continues below. TORONTO, ONTARIO, June 13, 2022 (GLOBE NEWSWIRE) Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (Aeterna or the Company), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced its Autoimmunity Modifying (AIM) Biologicals program has achieved pre-clinical proof-of-concept for the potential treatment of neuromyelitis optica spectrum disorder (NMOSD) (also known as Devic disease), a chronic autoimmune disorder of the brain and spinal cord dominated by inflammation of the optic nerve and spinal cord and which can be fatal in approximately 30% of patients within five years of diagnosis